Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.47.6_suppl_3.200s | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.
PLoS One
October 2024
Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Background: Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice.
Methods: We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS.
Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach.
J Mol Neurosci
February 2024
Department of Biotechnology, PES University, Bangalore, 560085, India.
The conventional method of one drug being used for one target has not yielded therapeutic solutions for Lewy body dementia (LBD), which is a leading progressive neurological disorder characterized by significant loss of neurons. The age-related disease is marked by memory loss, hallucinations, sleep disorder, mental health deterioration, palsy, and cognitive impairment, all of which have no known effective cure. The present study deploys a network medicine pipeline to repurpose drugs having considerable effect on the genes and proteins related to the diseases of interest.
View Article and Find Full Text PDFToxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
J Neural Transm (Vienna)
June 2024
Clinical Neurochemistry, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Würzburg, Germany.
Article Synopsis
- Parkinson's disease involves the loss of dopamine neurons and the buildup of harmful proteins, particularly α-synuclein, highlighting the importance of dopamine in its pathology.
- Beneficial treatments like L-DOPA point to dopamine deficits as a key factor, but multiple genetic and environmental elements contribute to the disease as it impacts other neurotransmitter systems as well.
- Interactions among dopamine, α-synuclein, and certain enzymes like monoamine oxidase are crucial; compounds like rasagiline and selegiline show promise in protecting neurons by preventing harmful changes and modifying these interactions.
The novel design of an intelligent anti-depression transdermal drug delivery system.
Biomaterials
December 2023
Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China. Electronic address:
Depression is a type of mental disorder with a significant and persistent low mood as the main clinical feature. It is often accompanied by symptoms such as slow thinking, decreased will, loss of appetite, and weight loss. The current treatment methods for depression are mainly medical treatment, psychotherapy, and physical therapy.
View Article and Find Full Text PDFExamination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST).
Front Neurol
October 2023
Department of Neurology and German Center for Vertigo and Balance Disorders, LMU University Hospital, LMU Munich, Munich, Germany.
Background: Betahistine was registered in Europe in the 1970s and approved in more than 80 countries as a first-line treatment for Menière's disease. It has been administered to more than 150 million patients. However, according to a Cochrane systematic review of betahistine and recent meta-analyses, there is insufficient evidence to say whether betahistine has any effect in the currently approved dosages of up to 48 mg/d.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!